Targeting Kinetoplastid Parasites with ProTide Prodrugs: A Proof‐of‐Concept Study
= 5 nM; selectivity index, SI = 2,560) against T. b. rhodesiense with robust activity also observed against T. cruzi and L. donovani. These findings establish the ProTide prodrug technology as a promising strategy for optimizing nucleoside analogues against kinetoplastid parasites and provide a framework for the development of new therapeutics for NTDs.
Authors
- Silvester Lowe
- Hachemi Kadri
- Marcel Kaiser (ORCID: https://orcid.org/0000-0003-1785-7302)
- Monica Cal (ORCID: https://orcid.org/0009-0007-9959-9891)
- Tanjia M. Syeda
- V Satikuvar
- Pascal Mäser
Institutions
- Swiss Tropical and Public Health Institute (CH)
- Kingston University London (GB)
- Kingston University (US)
Publication Details
- Journal
- ChemMedChem
- Published
- 2026-04-03
- DOI
- https://doi.org/10.1002/cmdc.202501072
- Primary Topic
- Trypanosoma species research and implications
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Global Challenges Research Fund
- Royal Society of Chemistry
- Medical Research Council